It Seems Achaogen, Inc. (AKAO) Will Go Down. Just Reaches 52-Week Low

July 16, 2018 - By Lisa Delgado

Achaogen, Inc. (NASDAQ:AKAO) Logo

Investors sentiment decreased to 1.02 in Q1 2018. Its down 0.30, from 1.32 in 2017Q4. It turned negative, as 17 investors sold Achaogen, Inc. shares while 28 reduced holdings. 22 funds opened positions while 24 raised stakes. 25.38 million shares or 14.67% less from 29.75 million shares in 2017Q4 were reported.
Lord Abbett & Ltd Liability Co holds 0.01% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 365,203 shares. Alpinvest Ptnrs Bv stated it has 2.55% in Achaogen, Inc. (NASDAQ:AKAO). Schwab Charles Invest Inc has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Quantitative Inv Management Ltd Liability Corp owns 93,700 shares. Northern Tru Corp has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Nea Mgmt Lc stated it has 5.22M shares or 3% of all its holdings. Citigroup accumulated 0% or 105,197 shares. State Street reported 3.10 million shares. Voya Investment Management Ltd Llc holds 0% or 15,435 shares. Goldman Sachs Grp holds 0% or 351,670 shares. Tower Rech Capital Limited Liability (Trc) holds 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 754 shares. Rmb Management Limited Company holds 0.04% or 127,407 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,712 shares. Ameritas Inv Prtnrs stated it has 2,546 shares. Deutsche Fincl Bank Ag holds 0% or 474,271 shares.

Since February 13, 2018, it had 10 insider buys, and 11 insider sales for $28.83 million activity. $49,146 worth of Achaogen, Inc. (NASDAQ:AKAO) was sold by Hillan Kenneth J. on Wednesday, February 21. Another trade for 2,087 shares valued at $24,940 was made by Schilke Tobin on Monday, June 11. Dorling Janet had sold 450 shares worth $4,316. Wise Blake also sold $17,499 worth of Achaogen, Inc. (NASDAQ:AKAO) on Wednesday, February 21. Another trade for 1,282 shares valued at $13,679 was sold by Swem Lee. LOEB GARY had sold 324 shares worth $3,107 on Tuesday, June 26.

The stock of Achaogen, Inc. (NASDAQ:AKAO) hit a new 52-week low and has $6.51 target or 9.00 % below today’s $7.16 share price. The 8 months bearish chart indicates high risk for the $320.67 million company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $6.51 price target is reached, the company will be worth $28.86 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 8.46% or $0.6617 during the last trading session, reaching $7.1583. About 1.38 million shares traded or 3.98% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has declined 48.54% since July 16, 2017 and is downtrending. It has underperformed by 61.11% the S&P500.

Analysts await Achaogen, Inc. (NASDAQ:AKAO) to report earnings on August, 2. They expect $-0.92 earnings per share, down 17.95 % or $0.14 from last year’s $-0.78 per share. After $-0.98 actual earnings per share reported by Achaogen, Inc. for the previous quarter, Wall Street now forecasts -6.12 % EPS growth.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 8 analysts covering Achaogen (NASDAQ:AKAO), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Achaogen had 11 analyst reports since February 14, 2018 according to SRatingsIntel. The company was maintained on Wednesday, February 28 by Mizuho. Wedbush maintained the shares of AKAO in report on Wednesday, February 14 with “Buy” rating. The firm earned “Buy” rating on Wednesday, June 27 by Mizuho. On Wednesday, May 2 the stock rating was maintained by Cowen & Co with “Buy”. Needham maintained it with “Buy” rating and $2000 target in Tuesday, June 26 report. Stifel Nicolaus maintained it with “Buy” rating and $23 target in Wednesday, February 28 report. As per Wednesday, February 28, the company rating was maintained by Needham. Wedbush maintained the stock with “Outperform” rating in Wednesday, June 27 report. Guggenheim downgraded Achaogen, Inc. (NASDAQ:AKAO) on Monday, May 7 to “Neutral” rating.

More notable recent Achaogen, Inc. (NASDAQ:AKAO) news were published by: Investorplace.com which released: “10 Strong Buy Stocks for Under $10” on July 12, 2018, also Seekingalpha.com with their article: “Achaogen to host lunch updating investors on commercial strategy post FDA approval of Plazomicin” published on July 11, 2018, Benzinga.com published: “Achaogen In The Spotlight Ahead of FDA Verdict On Plazomicin” on June 24, 2018. More interesting news about Achaogen, Inc. (NASDAQ:AKAO) were released by: Seekingalpha.com and their article: “Achaogen: Zemdri To The Rescue” published on July 10, 2018 as well as Seekingalpha.com‘s news article titled: “Achaogen: Falling Knife Or Major Bargain?” with publication date: June 28, 2018.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $320.67 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.